Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1010)	7/15/1998 1:04:00 PM
From: Don Walster	Respond to of 1491

Dear Ariella: Thank you for the encouraging news from Omer Shvili. If there is concern about current and anticipated sources of income before the 3 to 4 year wait, I think the following post on Yahoo from Dr. Cappiello, a reliable medical resource, should be encouraging. Kindest regards, Don Top:Business and Finance:Stocks:Healthcare:Biotechnology and Drugs:PARS (Pharmos Corp.) alrex/lotemax DCappiello Jul 14 1998 10:18PM EDT I would have to agree with some of the previous posts. These drugs are still not widely known, although BOL has begun to market them to select physicians. My rep left me with about 24 bottles of each and I have been using them with good results. I haven't written any prescriptions yet because I am still assessing the drugs and using my remaining samples. Since I am almost out of samples, I will begin to actively write for the drugs in the next week or so. Also, I know that BOL is spending a great deal of time working with managed care companies to get the drugs on their formulary. This is critical because non-formulary drugs will not have anywhere near as big a market. There have been several articles in our trade journals about them and large 2-page ads are running everywhere. So BOL is definitely starting to push them. The allergy season is in a bit of a lull right now but should kick into gear again soon (at least in California). I believe Alrex will be a big seller since it works so well, but we need to get the information out to more docs, and we need the marketing copartner to talk to GP's. I hear the copartner is Astra Pharmaceuticals, but that is not confirmed. Also PARS has not decided to endorse a copartner yet. I believe the LE-T will be a huge hit. It will compete head to head with Alcon's Tobradex, which is their number one seller. Tobradex is very expensive, and if LE-T comes in at a better price, the HMO's will eat it up. I am told BOL wants to better the price of Alcon's drugs and is very aware of the need to sell to HMO's. There is still a LOT of profit to be made in drugs. A bottle of ALrex can sell wholesale for $17-18 for 5 cc's, but probably costs less than a dollar to produce in large quantity. Pars receives only a small percentage of revenue, but they have NO overhead at this point, since BOL does all the production, distribution and marketing. I estimate it will take until next year before any significant earnings come in from these drugs, but think about all the things we can look forward to at that time-- possible approval of LE-T, possible start of phase III for HU-211, significant revenue from alrex/lotemax, and possible further results from tamoxifen as an angiogenesis inhibitor (remember Entremed?). Pharmos is a well run, highly focused company with a CEO that has proven he can deliver. Short sellers are manipulating the stock and are having a field day. I feel certain we will all wake up one day, turn on our computers and find Pars WAY up as some bit of news creates buying demand and the shorts get squeezed. I have nearly 35,000 shares and I'm hanging in there.